Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.32 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8250301 | 1.00 | CTSB (0.42) | CTSBPPP3CBCYP3A4CTSSMCL1 | |
| SCHEMBL12383126 | 0.92 | CTSB (0.35) | CTSBPPP3CBCYP3A4CTSSMCL1 | |
| SCHEMBL11888411 | 0.92 | ABCC1 (0.37) | CTSBPPP3CBCYP3A4CTSSMCL1 | |
| SCHEMBL7936992 | 0.91 | CTSB (0.48) | CTSBPPP3CBCYP3A4CTSSABCC1 | |
| SCHEMBL14095423 | 0.90 | CYP3A4 (0.43) | CTSBPPP3CBCYP3A4MCL1ABCC1 | |
| SCHEMBL8242872 | 0.89 | CTSB (0.48) | CTSBPPP3CBCYP3A4CTSSMCL1 | |
| SCHEMBL2215312 | 0.89 | CTSB (0.48) | CTSBPPP3CBCYP3A4CTSSMCL1 | |
| SCHEMBL12358243 | 0.89 | CTSB (0.40) | CTSBPPP3CBCYP3A4CTSS | |
| SCHEMBL13385384 | 0.89 | CTSB (0.50) | CTSBPPP3CBCYP3A4MCL1ABCC1 | |
| SCHEMBL12035180 | 0.89 | CTSB (0.50) | CTSBPPP3CBCYP3A4MCL1ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700552-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-7700552-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | CTSB 404/4885PPP3CB 1055/4885CYP3A4 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.